Welcome to the e-CCO Library!

P594: Vedolizumab dose intensification does not always improve treatment persistence.
Year: 2022
Source: ECCO'22
Authors: Hilley, P.(1);Peterson, A.R.(1);Wong , D.(1,2);Hine, K.(1);Srinivasan, A.(1);Choy, M.C.(1,2);De Cruz, P.(1,2);
Created: Friday, 11 February 2022, 3:56 PM
P595 Feasibility and performance of a fully automated endoscopic disease severity grading tool for ulcerative colitis using unaltered multisite videos
Year: 2020
Source:

ECCO'20 Vienna

Authors:

R. Stidham1,2, H. Yao3, S. Bishu1, M. Rice1, J. Gryak3, H.J. Wilkins4, K. Najarian2,3,5

Created: Thursday, 30 January 2020, 10:12 AM
P595: Clinical effectiveness of golimumab: Interim analysis of the observational study of patients with ulcerative colitis on golimumab in the Swedish National Quality Registry for IBD–GO-SWIBREG
Year: 2018
Source: ECCO '18 Vienna
Authors:

C. Eriksson1, D. Bergemalm1*, L. Vigren2, L. Nilsson3, I. Visuri1, H. Hjortswang4, R. Udumyan5, S. Almer6, M. Seddighzadeh7, E. Hertervig8, P. Karlén3, H. Strid9, J. Halfvarson1, The GO-SWIBREG study group

Created: Thursday, 21 February 2019, 9:14 AM
P595: Early medical therapy and risk of subsequent perianal fistula development among paediatric patients with Crohn’s disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

J. Adler*1,2, C. C. Lin3, S. Gadepalli2,4, K. Dombkowski2

Created: Friday, 22 February 2019, 9:41 AM
P595: Finding predictors of azathioprine-induced pancreatitis in patients with inflammatory bowel disease
Year: 2021
Source: ECCO'21 Virtual
Authors: Freitas, M.(1,2,3);Capela, T.(1,2,3);Macedo Silva, V.(1,2,3);Arieira, C.(1,2,3);Cúrdia Gonçalves, T.(1,2,3);Dias de Castro, F.(1,2,3);Moreira, M.J.(1,2,3);Cotter, J.(1,2,3);
Created: Wednesday, 2 June 2021, 4:12 PM
P595: The influence of vitamin D on expression of cytokines mRNA in IBD
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Leskova Z.*1, Krajčovičová A.1, Šoltys K.2, Stuchlík S.2, Šturdík I.1, Koller T.1, Huorka M.1, Hlavatý T.1

Created: Wednesday, 20 February 2019, 10:36 AM
P595: Time of Therapeutic Drug Monitoring of infliximab during induction and its relationship with clinical remission in Inflammatory Bowel Disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Muñoz-Villafranca, C.(1);Arreba , P.(1);Gomez, M.(2);Ispizua Madariaga, N.(1)*;Buendia, L.(1);Lopez, M.L.(1);Ugarte, A.(1);de la Fuente, I.(1);Prado, N.(1);Irusta, L.(1);Jimenez, M.A.(1);Santa Cruz, M.(1);Gonzalez, M.(1);Bilbao, A.(3);Ortiz de Zárate, J.(1);
Created: Friday, 14 July 2023, 11:05 AM
P595: Validation of a predictive algorithm for thiopurine induced hepatotoxicity in IBD patients
Year: 2022
Source: ECCO'22
Authors: Van Moorsel, F.(1,2);Deben, D.(3);Creemers, R.(4,5);Winkens, B.(6);Pierik, M.(7);Bus, P.(8);Simsek, M.(9);de Boer, N.(9);van Bodegraven, A.(4);Wong, D.(3);
Created: Friday, 11 February 2022, 3:56 PM
P596 Risk of colorectal cancer and other malignancies in association with the use of thiopurines, tumour necrosis factor antagonists or mesalazine
Year: 2020
Source:

ECCO'20 Vienna

Authors:

S. Timeus1, R. Laoun2

Created: Thursday, 30 January 2020, 10:12 AM
P596: Adalimumab use in Paediatric Inflammatory Bowel Disease: A single centre real-life experience
Year: 2022
Source: ECCO'22
Authors: El-Lababidi, N.(1,2);Frühauf, P.(2,2);
Created: Friday, 11 February 2022, 3:56 PM
P596: An ongoing safety registry to identify rare and severe complications in children with paediatric-onset IBD
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

M. A. Aardoom*1, P. Kemos2, F. Ruemmele3, N. Croft2, L. de Ridder1, PIBD SETQuality consortium and PIBDnet1

Created: Friday, 22 February 2019, 9:41 AM
P596: Clinical utility of vedolizumab trough levels and anti-drug antibodies in the management of IBD
Year: 2018
Source: ECCO '18 Vienna
Authors:

D. Jelk1, M. Perreau2, P. Michetti3, M. Maillard2*

Created: Thursday, 21 February 2019, 9:14 AM
P596: FMT in patients with steroid dependant ulcerative colitis a single centre observational study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Grewal C.S.1, Sood A.2, Mehta V.*2, Kaur D.3

Created: Wednesday, 20 February 2019, 10:36 AM
P596: Trough concentration of ustekinumab was a useful biomarker for the prediction of treatment-effects in patients with Crohn’s Diseases.
Year: 2021
Source: ECCO'21 Virtual
Authors: Kato, S.(1);Yamaga, N.(1);Ishibashi, A.(1);Kani, K.(1);Yakabi, K.(1);Nagoshi, S.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P596: Ustekinumab and anti-TNF agents are equally safe and effective in elderly Crohn's disease patients: A propensity adjusted multi-centre cohort study
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Gebeyehu, G.G.(1);Broglio, G.(2);Liu, E.(3);Limdi, J.K.(4);Selinger, C.(5);Fiske, J.(1);Razsanskaite, V.(1);Smith, P.J.(1);Flanagan, P.K.(6);Subramanian, S.(7)*;
Created: Friday, 14 July 2023, 11:05 AM
P597 Pooled safety analyses from Phase 3 studies of filgotinib in patients with rheumatoid arthritis
Year: 2020
Source:

ECCO'20 Vienna

Authors:

R. Besuyen1, D. Walker2, K. Winthrop3, M. Genovese4, B. Combe5, Y. Tanaka6, A. Kivitz7, F. Matzkies8, B. Bartok9, L. Ye10, Y. Guo10, C. Tasset1, J. Sundy11, E. Keystone12, R. Westhovens13, W. Rigby14, G. Burmester15

Created: Thursday, 30 January 2020, 10:12 AM
P597: Bone mineral density in patients after total proctocolectomy and pouch surgery due to Ulcerative Colitis have low bone mineral density, and low performance of DXA scans- a cross sectional study
Year: 2022
Source: ECCO'22
Authors: Pfeffer-Gik, T.(1,2);Godny, L.(1,2);Ollech , J.(1,2);Wasserberg, N.(2,3);Barkan , R.(1);White, I.(2,3);Yackobovitch Gavan, M.(4,5);Kraizler, M.(1);Yanai , H.(1,2);Dotan, I.(1,2);
Created: Friday, 11 February 2022, 3:56 PM
P597: Cycling Anti-TNF Therapy in Inflammatory Bowel Disease: Effectiveness and Durability of Switching from adalimumab to infliximab
Year: 2021
Source: ECCO'21 Virtual
Authors: Steinberg, J.(1);Andersen, M.(1);Krugliak Cleveland, N.(1);Traboulsi, C.(1);Rodriguez, T.(1);Cohen, R.(1);Dalal, S.(1);Micic, D.(1);Pekow, J.(1);Atsushi, S.(1);Rubin, D.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P597: Effectiveness and safety of vedolizumab therapy in an ulcerative colitis cohort with significant prior anti-TNF exposure
Year: 2018
Source: ECCO '18 Vienna
Authors:

C. Judge1,2*, N. McGettigan2,3, T. Ryan2,4, K. Hazel2,5, P. Singh2,6, V. Parihar2,6, R. Stack2,7, A. O'Connor2,8, C. Dunne1,2, G. Cullen2,4, L. Egan2,3, G. Harewood2,7, F. MacCarthy1,2, S. McKiernan1,2, H. Mulcahy2,4, F. Murray2,7, S. Patchett2,7, J. Sheridan2,4, D. Trevian2,7, N. Breslin2,8, R. Farrell2,5, J. Keohane2,6, O. Kelly2,5, D. McNamara2,8, B. Ryan2,8, C. Smyth2,5, C. O'Morain2,9, S. Sengupta2,6, E. Slattery2,3, G. Doherty2,4, D. Kevans1,2, A. O'Toole2,7

Created: Thursday, 21 February 2019, 9:14 AM
P597: Optimising therapeutic drug monitoring of adalimumab with dried blood samples in IBD patients: an interim analysis
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

S. Berends*1,2, K. Bloem3, R. Talwar1, A. De Vries3, T. Schaap3, A. Strik2, M. Löwenberg2, G. D'Haens2, R. Mathôt1

Created: Friday, 22 February 2019, 9:41 AM